Karen H. Costenbader, MD, MPH, Associate Professor of Medicine at Harvard Medical School and Associate Physician and Director of the Lupus Program at Brigham and Women’s Hospital, Boston, will shed light on how genetic and environmental factors interact in the development of SLE.

You’re invited to attend the American College of Rheumatology (ACR) annual business meeting, where the installation of the 80th ACR President, Sharad Lakhanpal, MBBS, MD, will take place.

“The current treatment is far from optimal,” said Michael Doherty, FRCP, MA, MD, professor of rheumatology at the University of Nottingham in the United Kingdom. “Gout is the only curable chronic arthritis, so why is this curable condition just not being cured?”

Candida Fratazzi, MD, the president of BBCR Consulting in Cambridge, Massachusetts, who will speak during Emerging Biosimilars in Therapeutic Management: Where We Are and What Is in the Future.

“It is quite an exciting time for psoriatic arthritis because we are getting new drugs that are specific for this disease,” said Laura C. Coates, MBChB, PhD, National Institute for Health Research Clinical Lecturer in Rheumatology at the University of Leeds, United Kingdom.

A Wednesday ARHP session will provide an update on sarcopenia research, diagnosis, and treatment, with a focus on the development of criteria that could be applied universally to help identify the issue that can have serious implications on patient well-being and everyday life.

Alan N. Baer, MD, Associate Professor of Medicine and Director of the Jerome Greene Sjögren’s Syndrome Clinic at Johns Hopkins University School of Medicine in Baltimore, will outline the differential diagnosis and an evaluation strategy for patients with salivary and lacrimal gland enlargement.

Patients don’t fit into a rheumatoid arthritis box or osteoarthritis box, and with the hundreds of nuanced, distinct diagnoses available, one treatment plan doesn’t fit all, says Seth D. Ginsberg, Co-Founder and President of the Global Healthy Living Foundation.

In one talk during the session, Nir Hacohen, PhD, Associate Professor of Medicine at Harvard Medical School and the director of Massachusetts General Hospital’s Center for Cancer Immunotherapy, will discuss a project aimed at defining dendritic cell and monocyte subtypes that are present in humans using RNAseq.